Fasting levels of growth hormone are associated with carotid intima media thickness but are not affected by fluvastatin treatment

Table 3 Characteristics of the BCAPS population after medical treatment

Variable	Placebo/Placebo	Metoprolol/Placebo	Fluvastatin/Metoprolol	Fluvastatin/Placebo
12 months
LDL-C, mean (SD), mmol/L	4.01 (0.82)	4.17 (0.87)	3.21 (0.85)	3.27 (0.74)
Growth Hormone - males, median (IQR), μg/L	0.16 (0.08-0.59)	0.17 (0.04-0.57)	0.21 (0.06-0.95)	0.12 (0.07-0.44)
Growth Hormone - females, median (IQR), μg/L	0.82 (0.40-1.99)	0.93 (0.41-2.20)	1.25 (0.53-2.50)	0.88 (0.41-2.01)
36 months
IMT_mean CCA, median (IQR)	0.91 (0.82-1.04)	0.90 (0.83-1.02)	0.87 (0.78-0.98)	0.87 (0.77-0.99)
IMT_max Bulb, median (IQR)	1.98 (1.71-2.35)	1.89 (1.60-2.43)	1.99 (1.60-2.44)	2.02 (1.68-2.30)

Missing values in IMT_mean CCA: placebo/placebo, n = 4; metoprolol/placebo n = 1; fluvastatin/placebo, n = 1
Missing values in IMT_max Bulb: placebo/placebo, n = 6; metoprolol/placebo n = 4; Fluvastatin/Metoprolol, n = 6; fluvastatin/placebo, n = 8
Missing values in LDL-C: placebo/placebo, n = 2; metoprolol/placebo n = 6; Fluvastatin/Metoprolol, n = 1; fluvastatin/placebo, n = 3

ISSN: 1471-2261